01 Growing Biobanking ActivitiesThe growing number of biobanks for storing biological samples, such as cells, tissues, and DNA, drives demand for cell-freezing media. Biobanks play an important role in medical research, personalized medicine, and drug discovery because they provide researchers access to a diverse range of well-characterized biological samples for scientific studies. Cell freezing media is critical for preserving the viability and integrity of cells maintained in biobanks for long periods, thereby driving market expansion.The UK Biobank is a large-scale biological database and research resource that houses de-identified genetic and health data from 500,000 UK residents. These samples are cryopreserved using a specialized cell freezing medium to ensure their integrity and viability throughout time. The database is available to accredited academics and scientists worldwide who study common and life-threatening diseases. The UK Biobank's open-access philosophy has resulted in external investment in resource development, allowing foreign scientists to undertake exceptional research. Further, In November 2023, AIG Hospitals in Gachibowli, Hyderabad, opened the first private biobank in South India. The biobank can keep over 300,000 human tissue samples for scientific research for over 15 years. It includes 15 freezers at -80°C, five at -20°C, and three liquid nitrogen tanks at -160°C.In addition, the organization Revive & Restore and the US Fish & Wildlife Service will launch a biobanking effort in 2023 to preserve the genetic variety of endangered species in the United States. This is the United States' first systematic biobanking pipeline for threatened or endangered species. The program collaborates with several institutions to create a legacy of America's natural heritage.The expanding global prevalence of biobanking operations is creating significant demand for cell freezing mediums, which are required for the cryopreservation of cells held in biobanks. Cell freezing media are used by researchers and biobank operators to preserve the integrity and viability of cells during long-term preservation, ensuring that the samples can be analyzed and experimented on. As biobanking activities grow and diversify, demand for high-quality cell freezing media is predicted to rise, propelling the market growth for these critical biopreservation solutions.
01 Health and Safety ConcernsCell freezing media frequently contain cryoprotectants, such as dimethyl sulfoxide (DMSO), which can endanger users' health and safety. Exposure to DMSO fumes or skin contact might cause irritation, allergic reactions, or respiratory issues in sensitive people. Furthermore, DMSO has been linked to cytotoxic effects on cells at high doses, potentially jeopardizing cell viability and functionality during cryopreservation. These health and safety issues may discourage researchers and biobanking centres from utilizing cell freezing media containing DMSO or other potentially hazardous cryoprotectants, limiting market expansion.The National Institute for Occupational Safety and Health (NIOSH) classifies DMSO as a hazardous chemical because of the potential health risks to workers who handle the substance. To reduce the possibility of adverse health effects, NIOSH recommends limits for workplace DMSO vapour exposure. Furthermore, studies have shown that occupational exposure to DMSO causes skin sensitivity, allergic responses, and respiratory problems in laboratory personnel. To safeguard the health and safety of laboratory workers, the Occupational Safety and Health Administration (OSHA) and other regulatory authorities issue rules and recommendations for the proper handling, storage, and disposal of DMSO and other hazardous chemicals.
01 Rising Demand for Personalized MedicinePersonalized medicine relies heavily on patient-specific cells and tissues to tailor therapy techniques to individual patients' genetic composition, illness features, and treatment responses. For example, in cancer treatment, patient-derived or circulating tumour cells (CTCs) are cryopreserved in cell-freezing media to allow for genetic profiling, drug sensitivity testing, and therapeutic decision-making. Oncologists can identify actionable targets, choose appropriate medicines, and monitor therapy responses by studying patient-derived cells' genetic alterations, gene expression patterns, and signalling pathways, resulting in more accurate and effective cancer care.Further, The growing use of customized medicine approaches, fuelled by advances in genomics, molecular diagnostics, and targeted medicines, is propelling market expansion. Personalized medicine initiatives use patient-specific cells and tissues for disease modelling, drug screening, and therapeutic interventions, increasing demand for cell-freezing media to cryopreserve these precious biological specimens.
June 2026 BioLife Solutions continued strengthening its cryopreservation solutions portfolio for cell and gene therapy applications through its CryoStor® cell freezing media platform. The company continued supporting advanced therapy developers with serum-free, GMP-compatible cryopreservation media designed to maintain cell viability during freezing, storage, and thawing processes.
May 2026 Sartorius expanded its focus on cell and gene therapy manufacturing workflows by advancing integrated solutions covering cell processing, storage, and preservation. The company continued developing technologies supporting scalable production and handling of therapeutic cells, including cryopreservation-related applications.
March 2026 Thermo Fisher Scientific continued expanding its bioproduction and cell therapy solutions portfolio, including cryopreservation reagents and workflow solutions used in research, biotechnology, and cell therapy manufacturing. The company focused on supporting scalable cell therapy development with improved preservation and processing technologies.
February 2026 Merck KGaA continued advancing its BioReliance® and cell culture solutions portfolio, supporting pharmaceutical and biotechnology companies involved in cell-based research and advanced therapy manufacturing. The company continued developing high-quality reagents and solutions used across cell processing workflows, including preservation applications.